<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Therence Bois on Medium]]></title>
        <description><![CDATA[Stories by Therence Bois on Medium]]></description>
        <link>https://medium.com/@therence?source=rss-12bff5227bd3------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*Vpkwz8w24waLRapMjXoAJw.jpeg</url>
            <title>Stories by Therence Bois on Medium</title>
            <link>https://medium.com/@therence?source=rss-12bff5227bd3------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 13:27:09 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@therence/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Behind the Deal: eNuvio]]></title>
            <link>https://medium.com/front-row-ventures-blog/behind-the-deal-enuvio-1923e5d7cf1a?source=rss-12bff5227bd3------2</link>
            <guid isPermaLink="false">https://medium.com/p/1923e5d7cf1a</guid>
            <category><![CDATA[phd]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[university]]></category>
            <dc:creator><![CDATA[Therence Bois]]></dc:creator>
            <pubDate>Mon, 27 Aug 2018 18:01:09 GMT</pubDate>
            <atom:updated>2018-08-27T18:01:09.852Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*JylKppCbXKK0OY3l" /></figure><p>The next big industrial revolution will be <a href="https://medium.com/world-economic-forum/how-biotechnology-is-evolving-in-the-fourth-industrial-revolution-e97a9d68f291">powered by biology</a>. With my background in molecular and cellular medicine and being the only life-science geek at Front Row Ventures (for now), one of my personal mission was to find those biotech startups hiding in Montreal universities.</p><p>One of the first hidden gem that I came across was <a href="http://enuvio.com/">eNuvio</a>, a life-science tech company building cutting-edge lab-on-a-chip technologies for molecular electrophysiologists (Scientist studying electrical activity within a cell).</p><h4><strong>Why should you care?</strong></h4><p>Studying cellular electrophysiology matters a lot. The electrical activity happening in your body allows your eyes to see, your fingers to feel, your heart to beat, your brain to think and several other vital functions that allows you to live, hence the obvious importance of studying this type of cellular activity. From a disease biology perspective, understanding these electrical activities is also extremely important as any dysregulation can lead to the development of problems like cardiovascular disease and neurodegeneration.</p><p>The current “gold standard” technology available to scientists studying molecular electrophysiology, the manual patch-clamp, was developed in the 1980s and hasn’t evolved much since. Ask any scientists in the field: Mastering patch-clamp experiments is REALLY hard and takes several years before you can properly produce, let alone trust the data you’re producing…</p><p>In the pharmaceutical industry, electrophysiology experiments are crucial for detecting drugs that could have adverse side effects in patients. You wouldn’t be surprised to learn that performing these experiments were made mandatory by the regulatory bodies (e.g FDA) before even thinking of testing a new drug in a human population.</p><h4><strong>Why should you believe?</strong></h4><p>We believe that eNuvio is developing the next gold standard within this industry. The scientific community has been waiting decades for a new technology, but unfortunately the most recent advances are not affordable, nor adaptable to the specific needs of industry and academic scientists.</p><p>Hugo McGuire, eNuvio’s CEO, experienced first-hand the many problems that these old fashion technologies can cause. After several years in front of his microscope looking at cells and enduring through several failed experiments, he decided that enough was enough! And that’s when his journey to transform the field of molecular electrophysiology began. With his expertise in ion channel biophysics, molecular physiology and nano-microfabrication of biodevices, Hugo had the perfect profile to find a solution to the nightmare of every electrophysiologist.</p><p>On his way to develop the first prototype of what would become eNuvio’s first lab-on-a-chip, he joined forces with Élise Faure (CSO) and Mark Aurousseau (CTO) who both have several years of experience working in academia and within the pharmaceutical industry. Together, the co-founding team had the perfect combination of skills to bring eNuvio’s vision to life.</p><p>I followed them for several months, got to know eNuvio’s team from up close and saw the evolution of their technology from prototype to final product. After showing and talking to multiple scientists about eNuvio’s technology, I deeply believe that they will be able to have a massive positive impact on life-science research.</p><h4><strong>Why did we invest?</strong></h4><p>One of our investment thesis at FRV regarding the future of tech is that the next big industrial revolution will be powered by biotechnology. A limiting step to this revolution is the ability to extract large amounts of high quality data from biological systems.</p><p>eNuvio has everything to change this paradigm in the field of cellular electrophysiology. By simplifying and automating cellular electrophysiology testing, eNuvio’s device can dramatically boost research productivity by increasing data output 10-fold while also reducing the experimentation costs by approximately 6-fold. Furthermore, eNuvio’s device achieves this in a user friendly manner. Thanks to them, anyone, even you, can do molecular electrophysiology experiments. And eNuvio thinks big: the long term plan is to develop software that would allow automated data analysis in order to offer a fuller user-friendly and more data-driven experience.</p><p>Their lab-on-a-chip is the first of many of what we believe are technologies that will fundamentally reshape the way electrophysiology is done.</p><p>End that’s why we decided to join them and be part of their journey!</p><p><em>You’re working on a disruptive biotech company? you think you’re gonna be part of the next big bio revolution? Contact us at </em><strong><em>hello@frontrow.vc</em></strong><em>, we’d love to chat!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1923e5d7cf1a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/front-row-ventures-blog/behind-the-deal-enuvio-1923e5d7cf1a">Behind the Deal: eNuvio</a> was originally published in <a href="https://medium.com/front-row-ventures-blog">Front Row Ventures Blog</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Become an xVivo AI scholar and disrupt the pharmaceutical industry!]]></title>
            <link>https://medium.com/xvivo-ai/become-an-xvivo-ai-scholar-and-disrupt-the-pharmaceutical-industry-ba682235afb6?source=rss-12bff5227bd3------2</link>
            <guid isPermaLink="false">https://medium.com/p/ba682235afb6</guid>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[fellowship]]></category>
            <category><![CDATA[students]]></category>
            <category><![CDATA[scholarship]]></category>
            <dc:creator><![CDATA[Therence Bois]]></dc:creator>
            <pubDate>Sun, 08 Jul 2018 04:44:23 GMT</pubDate>
            <atom:updated>2018-07-10T17:42:14.096Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*eG2MFl0sGRKFmd_USgA_8Q.jpeg" /></figure><p>Artificial intelligence (AI) is changing the landscape of many industries. Industries like manufacturing, farming, and services are starting to see the effects of cutting-edge companies using AI. The pharmaceutical industry is next and is ripe for reinvention.</p><p>Several companies have started to use AI to reshape the pharmaceutical R&amp;D workflow, and <a href="http://invivoai.com/">InVivo AI</a> is one of them.</p><h3>The xVivo AI scholarship</h3><p>Students are often underestimated, yet at the same time they’re some of the most innovative, motivated, and impactful people around. At InVivo AI, we believe that school is an entrepreneurial sweet-spot, one in which students can experiment, tinker, and explore before going all-in on a single idea. We founded InVivo AI while we were still full-time grad students, trying to launch a company while at the same time balancing heavy lab obligations, so we were able to live this experience firsthand.</p><p>Now we want to double-down on student entrepreneurship with the xVivo AI Scholars Program. The goal of the program is to provide a tailor-made entrepreneurial experience to students who want to work on something big, without having to give up their academic commitments. Projects will be customized according to the interests and skill-set of the applicant. Fellowships are limited and will be awarded on a rolling basis. If you want to use technology to help solve some of the biggest challenges faced by today’s pharmaceutical industry, we want to hear from you!</p><h3>Am I eligible to apply? Ideal applicants will:</h3><ul><li>Be enrolled as a full-time student (undergrad, master’s, or PhD) or employed as a postdoc at an accredited university institution.</li><li>Be able to consistently commit a fixed amount of weekly hours to working on a part-time basis.</li><li>Have a strong understanding of machine learning, computer science, and statistics, acquired either through academic study, internships, or independent/personal projects.</li><li>Have a basic understanding of and interest in molecular biology, pharmacology, and the drug discovery process (and if not, a strong willingness to learn).</li><li>Be extremely independent and self-motivated, and be comfortable with ambiguity and uncertainty in day-to-day tasks.</li><li>Be able to demonstrate some prior interest in entrepreneurship and/or startups (ideally).</li></ul><p><strong>Applications are now open at:</strong></p><p><a href="https://docs.google.com/forms/u/1/d/e/1FAIpQLSdL66AvzipY8YimdjZz-aXARPAT_1dFXg9ztQMjhCAXvIYGaA/viewform?usp=send_form">The xVivo AI Scholars Program</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ba682235afb6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/xvivo-ai/become-an-xvivo-ai-scholar-and-disrupt-the-pharmaceutical-industry-ba682235afb6">Become an xVivo AI scholar and disrupt the pharmaceutical industry!</a> was originally published in <a href="https://medium.com/xvivo-ai">xVivo AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>